BACKGROUND: Lobular carcinoma of the male breast is rare. We sought to investigate the clinical characteristics, treatment, and outcomes of men and women with lobular breast cancer, using a population-based database. METHODS: We reviewed the Surveillance, Epidemiology, and End Results database 1988-2008 and identified patients with a lobular breast cancer diagnosis (invasive lobular carcinoma [ILC] and lobular carcinoma in situ [LCIS]) using the "International Classification of Diseases for Oncology, Third Edition" codes. Bivariate analyses compared the male and female patients on demographics, clinical characteristics, and treatment modalities. Multivariate logistic regression analysis determined the risk-adjusted likelihood of receiving treatment. Survival analysis was done and hazard ratios were obtained using Cox proportional models. RESULTS: Overall, 133,339 patients were identified, including 133,168 women (99.9%) and 171 men (0.1%). Most had ILC (82.08%). The median age was 66 ± 20 y for the men and 61 ± 21 y for the women. The men with ILC were more likely to have poorly differentiated tumors (26.45% versus 15.61%; P < 0.001) and stage IV disease (9.03% versus 4.18%; P = 0.005) than were the women. The cancer-specific 5-year survival rates for ILC were 82.9% for the men and 91.9% for the women. Adjusted survival was better for patients with ILC receiving surgery plus radiotherapy than patients receiving neither (hazard ratio 0.52, 95% confidence interval 0.49-0.56). Women with ILC had a 55% increased odds of receiving surgery plus radiotherapy compared with men (odds ratio 1.55, 95% confidence interval 1.08-2.22). CONCLUSIONS: ILC presents at a higher grade and stage in men. The difference in disease characteristics and survival rates suggests that the treatment of men with lobular breast cancer should be adjusted to improve their outcomes.
BACKGROUND:Lobular carcinoma of the male breast is rare. We sought to investigate the clinical characteristics, treatment, and outcomes of men and women with lobular breast cancer, using a population-based database. METHODS: We reviewed the Surveillance, Epidemiology, and End Results database 1988-2008 and identified patients with a lobular breast cancer diagnosis (invasive lobular carcinoma [ILC] and lobular carcinoma in situ [LCIS]) using the "International Classification of Diseases for Oncology, Third Edition" codes. Bivariate analyses compared the male and female patients on demographics, clinical characteristics, and treatment modalities. Multivariate logistic regression analysis determined the risk-adjusted likelihood of receiving treatment. Survival analysis was done and hazard ratios were obtained using Cox proportional models. RESULTS: Overall, 133,339 patients were identified, including 133,168 women (99.9%) and 171 men (0.1%). Most had ILC (82.08%). The median age was 66 ± 20 y for the men and 61 ± 21 y for the women. The men with ILC were more likely to have poorly differentiated tumors (26.45% versus 15.61%; P < 0.001) and stage IV disease (9.03% versus 4.18%; P = 0.005) than were the women. The cancer-specific 5-year survival rates for ILC were 82.9% for the men and 91.9% for the women. Adjusted survival was better for patients with ILC receiving surgery plus radiotherapy than patients receiving neither (hazard ratio 0.52, 95% confidence interval 0.49-0.56). Women with ILC had a 55% increased odds of receiving surgery plus radiotherapy compared with men (odds ratio 1.55, 95% confidence interval 1.08-2.22). CONCLUSIONS: ILC presents at a higher grade and stage in men. The difference in disease characteristics and survival rates suggests that the treatment of men with lobular breast cancer should be adjusted to improve their outcomes.
Authors: Valentina Silvestri; Daniel Barrowdale; Anna Marie Mulligan; Susan L Neuhausen; Stephen Fox; Beth Y Karlan; Gillian Mitchell; Paul James; Darcy L Thull; Kristin K Zorn; Natalie J Carter; Katherine L Nathanson; Susan M Domchek; Timothy R Rebbeck; Susan J Ramus; Robert L Nussbaum; Olufunmilayo I Olopade; Johanna Rantala; Sook-Yee Yoon; Maria A Caligo; Laura Spugnesi; Anders Bojesen; Inge Sokilde Pedersen; Mads Thomassen; Uffe Birk Jensen; Amanda Ewart Toland; Leigha Senter; Irene L Andrulis; Gord Glendon; Peter J Hulick; Evgeny N Imyanitov; Mark H Greene; Phuong L Mai; Christian F Singer; Christine Rappaport-Fuerhauser; Gero Kramer; Joseph Vijai; Kenneth Offit; Mark Robson; Anne Lincoln; Lauren Jacobs; Eva Machackova; Lenka Foretova; Marie Navratilova; Petra Vasickova; Fergus J Couch; Emily Hallberg; Kathryn J Ruddy; Priyanka Sharma; Sung-Won Kim; Manuel R Teixeira; Pedro Pinto; Marco Montagna; Laura Matricardi; Adalgeir Arason; Oskar Th Johannsson; Rosa B Barkardottir; Anna Jakubowska; Jan Lubinski; Angel Izquierdo; Miguel Angel Pujana; Judith Balmaña; Orland Diez; Gabriella Ivady; Janos Papp; Edith Olah; Ava Kwong; Heli Nevanlinna; Kristiina Aittomäki; Pedro Perez Segura; Trinidad Caldes; Tom Van Maerken; Bruce Poppe; Kathleen B M Claes; Claudine Isaacs; Camille Elan; Christine Lasset; Dominique Stoppa-Lyonnet; Laure Barjhoux; Muriel Belotti; Alfons Meindl; Andrea Gehrig; Christian Sutter; Christoph Engel; Dieter Niederacher; Doris Steinemann; Eric Hahnen; Karin Kast; Norbert Arnold; Raymonda Varon-Mateeva; Dorothea Wand; Andrew K Godwin; D Gareth Evans; Debra Frost; Jo Perkins; Julian Adlard; Louise Izatt; Radka Platte; Ros Eeles; Steve Ellis; Ute Hamann; Judy Garber; Florentia Fostira; George Fountzilas; Barbara Pasini; Giuseppe Giannini; Piera Rizzolo; Antonio Russo; Laura Cortesi; Laura Papi; Liliana Varesco; Domenico Palli; Ines Zanna; Antonella Savarese; Paolo Radice; Siranoush Manoukian; Bernard Peissel; Monica Barile; Bernardo Bonanni; Alessandra Viel; Valeria Pensotti; Stefania Tommasi; Paolo Peterlongo; Jeffrey N Weitzel; Ana Osorio; Javier Benitez; Lesley McGuffog; Sue Healey; Anne-Marie Gerdes; Bent Ejlertsen; Thomas V O Hansen; Linda Steele; Yuan Chun Ding; Nadine Tung; Ramunas Janavicius; David E Goldgar; Saundra S Buys; Mary B Daly; Anita Bane; Mary Beth Terry; Esther M John; Melissa Southey; Douglas F Easton; Georgia Chenevix-Trench; Antonis C Antoniou; Laura Ottini Journal: Breast Cancer Res Date: 2016-02-09 Impact factor: 6.466